David Kwiatkowski, MD
Medical Oncology · Boston, MANPI 1114010311
Payments from drug & device makers
Across 26 payments — averaging $39,931 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$810K
- Aadi Bioscience, Inc.$184K
- Novartis$41K
- F. Hoffmann-la Roche AG$3K
Across 9 payments — averaging $1705.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$11K
- F. Hoffmann-la Roche AG$5K
What the payments were for
- Speaking & faculty fees$3,32357%
- Travel & lodging$1,04118%
- Food & beverage$1222%
- Education$1,29522%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 16 | $810,331 |
| Aadi Bioscience, Inc. | 5 | $183,569 |
| Novartis | 1 | $40,974 |
| F. Hoffmann-la Roche AG | 4 | $3,323 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$3,323
- FYARRO$1,295
- Non-Covered Product$926
How this compares
$1,038,197 in reported general payments places this provider in the 75th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $7,303 |
| Dexamethasone | 27 | $180 |
| Prochlorperazine Maleate | 21 | $77 |
| Ondansetron Hcl | 19 | $39 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- Otto MetzgerBoston$141.9M
- Suzanne GeorgeBoston$88.5M
- Pasi Antero JanneBoston$67.2M
- Erica MayerBoston$51.8M
- Toni ChoueiriBoston$28.3M
- Laura SpringBoston$22.9M
- James ClearyBoston$18.8M
- Marlise LuskinBoston$18.7M
- Ana Garrido-CastroBoston$18M
- Jacob LaubachBoston$17.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.